HK Stock Market Move | NEWBORNTOWN(09911) rose more than 7% as the company's boutique gaming business entered the profitable stage, and has begun contributing revenue.
Techland Baby City Technology (09911) surged over 7%, as of the time of writing, it is up 6.86% at 4.05 Hong Kong dollars, with a trading volume of 1104.88 million Hong Kong dollars.
NEWBORNTOWN (09911) rose more than 7%, closing at a 6.86% increase, reaching 4.05 Hong Kong dollars, with a turnover of 1104.88 million Hong Kong dollars as of the deadline.
On the news front, on January 20, NEWBORNTOWN released unaudited operating data for the year 2024, disclosing for the first time the revenue contribution of the boutique game business to the listed company, indicating that the business has begun to be profitable. The announcement showed that boutique games such as Alice's Dream: Merge Games developed independently by the company and delivered for external distribution are profitable and the company receives a share of the profits. In 2024, the company's boutique games generated revenue of approximately 7.05 billion RMB, an increase of about 80.4% from 2023. The revenue contribution from the gaming business indicates that the company's layout in boutique games is starting to bear fruit, and the second growth curve is expected to erupt.
Related Articles

CISI FIN: Maintains "Buy" rating for BEAUTYFARM MED (02373) with a target price of HK$45.

Open Securities: The trend of "wealth management" for deposits is accelerating, and the advantages of comprehensive service-oriented banks are expanding.

JP Morgan is optimistic about the potential of the CRISPR gene editing pipeline and has initiated coverage with an "overweight" rating and a target price of $70 USD.
CISI FIN: Maintains "Buy" rating for BEAUTYFARM MED (02373) with a target price of HK$45.

Open Securities: The trend of "wealth management" for deposits is accelerating, and the advantages of comprehensive service-oriented banks are expanding.

JP Morgan is optimistic about the potential of the CRISPR gene editing pipeline and has initiated coverage with an "overweight" rating and a target price of $70 USD.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025